Capricor Therapeutics investors sue after stock plunges 64% on FDA briefing
AI Summary- Kaplan Fox filed a class action against Capricor Therapeutics on behalf of affected securities investors.
- Capricor shares fell $12.70, or 64%, to close at $7 on July 27, 2026.
- Investors must move the court by September 28, 2026, to seek lead-plaintiff status.